The UN authorizes the 1st mpox vaccine for children in an attempt to control the outbreak in Congo
The World Health Organization has authorized the first mpox vaccine for children
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The World Health Organization has authorized the first mpox vaccine for children, a decision experts hope will help make immunizations more widely available to one of the hardest-hit populations during the ongoing outbreaks of the disease in Congo and elsewhere in Africa.
In a statement late Tuesday, the U.N. health agency said it had approved the mpox vaccine made by Japanese company KM Biologics for use in children over 1 year of age as a single dose.
Earlier this month, the charity Save the Children said cases among children younger than 18 had increased by more than 130% in Congo, noting there were now more than 25,000 suspect cases.
The charity said children were almost four times more likely than adults to die from the newest form of mpox first detected in eastern Congo earlier this year. Mpox, related to smallpox, mostly causes symptoms including fever, rash, lesions and fatigue.
“Children are especially vulnerable to mpox,” Save The Children's Dr. Katia Veira de Moraaes Lecasse said in a statement. “They explore by touch and taste, don't always understand health guidance and have weaker immune systems than adults.”
Scientists have previously noted that mpox appears to be disproportionately affecting children in Congo and Burundi, which account for more than 90% of all mpox cases in Africa's current outbreak.
WHO had previously approved the mpox vaccine made by Bavarian Nordic for people 18 and over, but said the shot could be used in younger populations if doctors thought the benefits might outweigh potential risks, given the lack of data in children and other groups including pregnant women.
Last week, WHO said cases of mpox in the Congolese region where the new, more infectious form was first identified appeared to be “ plateauing,” even as cases were rising elsewhere, including Burundi and Uganda.
So far, about 50,000 people in Congo have been immunized against mpox with the vaccine made by Bavarian Nordic.
WHO said Japan had announced it would donate about 3 million doses of the shot made by KM Biologics to Congo. It was not clear whether any of the doses have arrived.
On Friday, WHO is convening its expert committee to determine whether the outbreaks in Congo and elsewhere in Africa is still a global emergency, a declaration the U.N. agency first made in August.
To date, Africa has reported more than 46,000 suspected mpox cases in the current outbreak, including 1,081 deaths.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.